TY - JOUR
T1 - Oxygenated Exosome-Based Nanoeyedrop for Mitigating Hypoxia in Corneal Wound Healing
T2 - Impact on Healing Properties of Human Corneal Epithelial Cells
AU - Han, Xiaoxue
AU - Ju, Leah
AU - Sands, Mia
AU - Zhao, Yunlei
AU - Irudayaraj, Joseph
N1 - The authors acknowledge the NSF grant STTR-PhaseII (#2236857) award. X.H. acknowledges the support from the Cancer Scholars for Translational and Applied Research (C*STAR) Program sponsored by the Cancer Center at Illinois and the Carle Cancer Center. Partial funding from the Health Maker Lab of the Carle Illinois College of Medicine and the Mikashi Award from the Institute of Genomic Biology, University of Illinois at Urbana\u2013Champaign is greatly appreciated. We acknowledge the Roy J. Carver Biotechnology Center at the University of Illinois at Urbana\u2013Champaign for assistance in sequencing. and TOC were created with BioRender.com made available through the Tumor Engineering and Phenotyping Shared Resource.
PY - 2025/2/14
Y1 - 2025/2/14
N2 - The rapid and organized healing of the cornea, while maintaining optical clarity, is essential for patient health and quality of life following corneal injuries. Oxygen plays a critical role in regulating cell migration and proliferation during wound repair, and the application of stem cell-derived exosomes offers potential therapeutic benefits due to their antioxidant and antiscarring properties. In this study, we developed oxygenated exosome-coated hemoglobin nanoparticles (OExo NPs) designed for effective oxygen delivery to enhance corneal re-epithelialization, reduce inflammation, and mitigate scarring. These OExo NPs exhibit a uniform average diameter of 130 nm and demonstrate consistent oxygen release capabilities. In vitro assays using human corneal epithelial cells-transformed (HCE-T) revealed that OExo NPs significantly promote cell proliferation and accelerate migration in scratch wound assays. Fluorescence imaging confirmed the successful internalization of OExo NPs into HCE-T cells and increased intracellular oxygen levels under hypoxic conditions. Gene expression analyses indicated a downregulation of critical wound healing markers, including HIF-1α, VEGF, IL-8, and FAK, suggesting effective alleviation of hypoxia, inhibition of angiogenesis, suppression of inflammation, and reduction of scar formation. These results highlight the potential of OExo NPs as a promising therapeutic approach for topical treatment of corneal wounds.
AB - The rapid and organized healing of the cornea, while maintaining optical clarity, is essential for patient health and quality of life following corneal injuries. Oxygen plays a critical role in regulating cell migration and proliferation during wound repair, and the application of stem cell-derived exosomes offers potential therapeutic benefits due to their antioxidant and antiscarring properties. In this study, we developed oxygenated exosome-coated hemoglobin nanoparticles (OExo NPs) designed for effective oxygen delivery to enhance corneal re-epithelialization, reduce inflammation, and mitigate scarring. These OExo NPs exhibit a uniform average diameter of 130 nm and demonstrate consistent oxygen release capabilities. In vitro assays using human corneal epithelial cells-transformed (HCE-T) revealed that OExo NPs significantly promote cell proliferation and accelerate migration in scratch wound assays. Fluorescence imaging confirmed the successful internalization of OExo NPs into HCE-T cells and increased intracellular oxygen levels under hypoxic conditions. Gene expression analyses indicated a downregulation of critical wound healing markers, including HIF-1α, VEGF, IL-8, and FAK, suggesting effective alleviation of hypoxia, inhibition of angiogenesis, suppression of inflammation, and reduction of scar formation. These results highlight the potential of OExo NPs as a promising therapeutic approach for topical treatment of corneal wounds.
KW - corneal wound healing
KW - drug delivery
KW - hypoxia mitigation
KW - nanomedicine
KW - scarring
UR - http://www.scopus.com/inward/record.url?scp=85215844950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215844950&partnerID=8YFLogxK
U2 - 10.1021/acsptsci.4c00724
DO - 10.1021/acsptsci.4c00724
M3 - Article
AN - SCOPUS:85215844950
SN - 2575-9108
VL - 8
SP - 602
EP - 612
JO - ACS Pharmacology and Translational Science
JF - ACS Pharmacology and Translational Science
IS - 2
ER -